As a representative agent of CDK4/6 inhibitors, ribociclib demonstrates common adverse reactions including hepatotoxicity (10), neutropenia, thrombocytopenia, QT interval prolongation, gastrointestinal disturbances such as nausea, diarrhea, and vomiting, along with fatigue (11). This evidence concerns the gene CDK4 and Thrombocytopenia.